IINN Q4 2023 Earnings Narrower Loss Surprises as Inspira Advances Clinical Milestones Ingredion Q1 2026 Earnings EPS Misses Estimates Amid Challenging Operating Environment Dyne Therapeutics Q1 2026 Earnings Narrower Loss Than Expected Drives Slight Stock Uptick SUPV Q1 2026 Earnings Massive EPS Beat Surprises Market Stock Declines Despite Strong Performance WRB Q1 2026 Earnings Strong Underwriting and Investment Performance Drive 124 EPS Beat BTE Q1 2026 Earnings Significant EPS Miss Highlights Operational Headwinds